In:
BioMed Research International, Hindawi Limited, Vol. 2017 ( 2017), p. 1-7
Abstract:
Aims . Patients with chronic kidney disease (CKD) and Helicobacter pylori ( H. pylori ) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies. This study aimed to assess the efficacy of a 7-day standard triple therapy in patients with CKD (eGFR 〈 60 ml/min/1.73 m 2 ) and to investigate the clinical factors influencing the success of eradication. Methods . A total of 758 patients with H. pylori infection receiving a 7-day standard first-line triple therapy between January 1, 2013, and December 31, 2014, were recruited. Patients were divided into two groups: CKD group ( N = 13 0 ) and non-CKD group ( N = 628 ). Results . The eradication rates attained by the CKD and non-CKD groups were 85.4% and 85.7%, respectively, in the per-protocol analysis ( p = 0 . 933 ). The eradication rate in CKD stage 3 was 84.5% (82/97), in stage 4 was 88.2% (15/17), and in those who received hemodialysis was 87.5% (14/16). There were no significant differences in the various stages of CKD ( p = 0 . 982 ). The adverse events were similar between the two groups (3.1% versus 4.6%, p = 0 . 433 ). Compliance between the two groups was good (100.0% versus 99.8%, p = 0.6 49 ). There was no significant clinical factor influencing the H. pylori eradication rate in the non-CKD and CKD groups. Conclusions . This study suggests that the H. pylori eradication rate and adverse rate in patients with CKD are comparable to those of non-CKD patients.
Type of Medium:
Online Resource
ISSN:
2314-6133
,
2314-6141
DOI:
10.1155/2017/3762194
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2017
detail.hit.zdb_id:
2698540-8
Permalink
